Pulmonary vasculitis: diagnosis and treatment


Cite item

Full Text

Abstract

Pulmonary vasculitis is a group of rapidly progressing severe diseases characterized by vascular inflammation, destruction and necrosis of the pulmonary tissue. The pathological process in the lungs varies from diffuse alveolar hemorrhage to inflammation of the parenchyma, pleural effusion, thrombotic and thromboembolic complications. Depending on the size of the affected vessels, vasculites are divided into vasculites of large, medium and small vessels. Most frequently the lung is found in the small vessels vasculitis, including ANCA-associated vasculitis [granulomatosis with polyangiitis (GP), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA)] and the disease is glomerular basement membrane (goodpasture syndrome). Clinical examination of other systems and organs involved in the pathological process, including the skin and kidneys, as well as the detection of autoantibodies can improve approaches to early diagnosis and treatment of vasculitis. Treatment of life-threatening pulmonary bleeding and irreversible damage to organs, especially the kidneys, requires rapid diagnosis of these conditions. Vasculitis is a rare disease with lesions of many organs, and methods of their treatment, including biological, are rapidly developing, which requires the cooperation of doctors of various specialties and specialized centers to achieve better control of the disease.

About the authors

E Kh Anaev

Pirogov Russian National Research Medical University

Email: el_anaev@hotmail.com
д.м.н., проф. каф. пульмонологии факультета дополнительного профессионального образования; ORCID iD 0000-0003-3672-9242 Moscow, Russia

I A Baranova

Pirogov Russian National Research Medical University

д.м.н., проф., проф. кафедры госпитальной терапии педиатрического факультета, ORCID iD 0000-0002-2469-7346 Moscow, Russia

A S Belevsky

Pirogov Russian National Research Medical University

д.м.н., проф., зав. каф. пульмонологии факультета дополнительного профессионального образования, ORCID iD 0000-0001-6050-724X Moscow, Russia

References

  1. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K. European Vasculitis Study Group. Long - term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011; 70(3): 488-494. https://doi: 10.1136/ ard.2010.137778
  2. Jennette J.C, Falk R.J, Bacon P.A, Basu N, Cid M.C, Ferrario F, Flores-Suarez L.F, Gross W.L, Guillevin L, Hagen E.C, Hoffman G.S, Jayne D.R, Kallenberg C.G, Lamprecht P, Langford C.A, Luqmani R.A, Mahr A.D, Matteson E.L, Merkel P.A, Ozen S, Pusey C.D, Rasmussen N, Rees A.J, Scott D.G, Specks U, Stone J.H, Takahashi K, Watts R.A. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1): 1-11. https://doi: 10.1002/ art.37715
  3. Jennette J.C, Falk R.J, Andrassy K, Bacon P.A, Churg J, Gross W.L, Hagen E.C, Hoffman G.S, Hunder G.G, Kallenberg C.G et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37(2): 187-192.
  4. Mandl L.A, Solomon D.H, Smith E.L, Lew R.A, Katz J.N, Shmerling R.H. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test - ordering guidelines improve diagnostic accuracy? Arch Intern Med. 2002; 162(13): 1509-1514.
  5. Frankel S.K, Sullivan E.J, Brown K.K. Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis. Crit Care Clinics. 2002; 18(4): 855-879.
  6. Swerlick R.A, Lawley T.J. Cutaneous vasculitis: its relationship to systemic disease. Med Clin North Am. 1989; 73(5): 1221-1235.
  7. Guillevin L, Lhote F, Gherardi R. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: clinical aspects, neurologic manifestations, and treatment. Neurol Clin. 1997; 15(4): 865-886.
  8. Davies D.J, Moran J.E, Niall J.F, Ryan G.B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982; 285(6342): 606.
  9. Choi H.K, Liu S, Merkel P.A, Colditz G.A, Niles J.L. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on myeloperoxidase antibodies. J Rheumatol. 2001; 28(7): 1584-1590.
  10. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk R.J, Hagen E.C, Jayne D, Jennette J.C, Paspaliaris B, Pollock W, Pusey C, Savage C.O, Silvestrini R, van der Woude F, Wieslander J, Wiik A. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999; 111(4): 507-513.
  11. Finkielman J.D, Lee A.S, Hummel A.M, Viss M.A, Jacob G.L, Homburger H.A, Peikert T, Hoffman G.S, Merkel P.A, Spiera R, St Clair E.W, Davis J.C. Jr, Mc Cune W.J, Tibbs A.K, Ytterberg S.R, Stone J.H, Specks U; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007; 120(7): 643. e9-14. 10.1016/j.amjmed.2006.08.016' target='_blank'>https://doi: 10.1016/j.amjmed.2006.08.016
  12. Mukhtyar C, Guillevin L, Cid M.C, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg C.G, Merkel P.A, Raspe H, Salvarani C, Scott D.G, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009; 68(3): 310-317. https://doi:10. 1136/ard.2008.088096
  13. Ananthakrishnan L, Sharma N, Kanne J.P. Wegener’s granulomatosis in the chest: high - resolution CT findings. AJR Am J Roentgenol. 2009; 192(3): 676-682. 10.2214/AJR.08.1837' target='_blank'>https://doi: 10.2214/AJR.08.1837
  14. Hoffman G.S, Kerr G.S, Leavitt R.Y, Hallahan C.W, Lebovics R.S, Travis W.D, Rottem M, Fauci A.S. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116(6): 488-498.
  15. Hauer H.A, Bajema I.M, van Houwelingen H.C, Ferrario F, Noël L.H, Waldherr R, Jayne D.R, Rasmussen N, Bruijn J.A, Hagen E.C; European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61(1): 80-89. 10.1046/j.1523-1755.2002' target='_blank'>https://doi: 10.1046/j.1523-1755.2002. 00089.
  16. Anderson G, Coles E.T, Crane M, Douglas A.C, Gibbs A.R, Geddes D.M, Peel E.T, Wood J.B. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub - committee of the British Thoracic Society Research Committee. Q J Med. 1992; 83(302): 427-438.
  17. Fauci A.S, Haynes B.F, Katz P, Wolff S.M. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98(1): 76-85.
  18. Cordier J.F, Valeyre D, Guillevin L, Loire R, Brechot J.M. Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest. 1990; 97: 906-912.
  19. Travis W.D, Hoffman G.S, Leavitt R.Y, Pass H.I, Fauci A.S. Surgical pathology of the lung in Wegener’s granulomatosis. Am J Surg Pathol. 1991; 15(4): 315-333.
  20. Mark E.J, Flieder D.B, Matsubara O. Treated Wegener’s granulomatosis: distinctive pathological findings in the lung of 20 patients and what they tell us about the natural history of the disease. Hum Pathol. 1997; 28: 450-458.
  21. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008; 26(Suppl 51): S94-104.
  22. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long - term follow - up of 96 patients. Medicine. 1999; 78(1): 26-37.
  23. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine. 1984; 63: 65-81.
  24. Comarmond C, Pagnoux C, Khellaf M, Cordier J.F, Hamidou M, Viallard J.F, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long - term follow up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013; 65(1): 270-281. 10.1002/art.37721' target='_blank'>https://doi: 10.1002/art.37721
  25. Katzenstein A.L. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol. 2000; 114(5): 767-772. 10.1309/F3FW-J8EB-X913-G1RJ' target='_blank'>https://doi: 10.1309/F3FW-J8EB-X913-G1RJ
  26. Keogh K.A, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003; 115(4): 284-290.
  27. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty - five patients. Arthritis Rheum. 1999; 42(3): 421-430. 3.0.CO;2-6'' target='_blank'>10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6' target='_blank'>https://doi: 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6
  28. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998; 7(4): 238-258. 10.1191/096120398678920055' target='_blank'>https://doi: 10.1191/096120398678920055
  29. Frankel S.K, Cosgrove G.P, Brown K.K. Small vessel vasculitis of the lung. Chron Respir Dis. 2005; 2(2): 75-84. https://doi: 10.1191/ 1479972305cd070rs
  30. Langford C.A, Talar-Williams C, Sneller M.C. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long - term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000; 43(8): 1836-1840. 10.1002/1529-0131' target='_blank'>https://doi: 10.1002/1529-0131 (200008)43:8<1836::AID-ANR20>3.0.CO;2-R
  31. Harper L, Morgan M.D, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez L.F, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage C.O, Jayne D; EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long - term follow - up. Ann Rheum Dis. 2012; 71(6): 955-960. 10.1136/annrheumdis-2011-200477' target='_blank'>https://doi: 10.1136/annrheumdis-2011-200477
  32. Stone J.H, Merkel P.A, Spiera R, Seo P, Langford C.A, Hoffman G.S, Kallenberg C.G, St Clair E.W, Turkiewicz A, Tchao N.K, Webber L, Ding L, Sejismundo L.P, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen N.B, Fervenza F.C, Geetha D, Keogh K.A, Kissin E.Y, Monach P.A, Peikert T, Stegeman C, Ytterberg S.R, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3): 221-232. 10.1056/NEJMoa0909905' target='_blank'>https://doi: 10.1056/NEJMoa0909905
  33. Schmitt W.H, Hagen E.C, Neumann I, Nowack R, Flores-Suárez L.F, van der Woude F.J; European Vasculitis Study Group. Treatment of refractory Wegeners granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004; 65(4): 1440-1448. 10.1111/j.1523-1755.2004.00534.x' target='_blank'>https://doi: 10.1111/j.1523-1755.2004.00534.x
  34. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end - stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol. 2002; 57(6): 421-424.
  35. Smith R.M, Jones R.B, Guerry M.J, Laurino S, Catapano F, Chaudhry A, Smith K.G, Jayne D.R. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody - associated vasculitis. Arthritis Rheum. 2012; 64(11): 3760-3769. 10.1002/art.34583' target='_blank'>https://doi: 10.1002/art.34583
  36. Cohen Tervaert J.W, Stegeman C.A, Kallenberg C.G. Novel therapies for anti - neutrophil cytoplasmic antibody - associated vasculitis. Curr Opin Nephrol Hypertens. 2001; 10(2): 211-217.
  37. Langford C.A, Sneller M.C. Biologic therapies in the vasculitides. Curr Opin Rheumatol. 2003; 15: 3-10.
  38. Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne D.R; European Vasculitis Study Group. Brief report: long - term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody - associated vasculitis. Arthritis Rheum. 2012; 64(10): 3472-3477. 10.1002/art' target='_blank'>https://doi: 10.1002/art. 34547
  39. Seo P, Specks U, Keogh K.A. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008; 35(10): 2017-2023.
  40. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Généreau T, Léon A, Bussel A. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty - two patients. Arthritis Rheum. 1995; 38(11): 1638-1645.
  41. Klemmer P.J, Chalermskulrat W, Reif M.S, Hogan S.L, Henke D.C, Falk R.J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small - vessel vasculitis. Am J Kidney Dis. 2003; 42(6): 1149-1153.
  42. Henke D, Falk R.J, Gabriel D.A. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med. 2004; 140(6): 493-494.
  43. Ahmed S.H, Aziz T, Cochran J, Highland K. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage. Chest. 2004; 126(1): 305-309. 10.1378/chest.126.1.305' target='_blank'>https://doi: 10.1378/chest.126.1.305
  44. Pagnoux C, Mahr A, Hamidou M.A, Boffa J.J, Ruivard M, Ducroix J.P, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier J.F, Guillevin L; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008; 359(26): 2790-2803. 10.1056/NEJMoa0802311' target='_blank'>https://doi: 10.1056/NEJMoa0802311
  45. Reinhold-Keller E, Fink C.O, Herlyn K, Gross W.L, De Groot K. High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance remission with low - dose methotrexate. Arthritis Rheum. 2002; 47(3): 326-332. 10.1002/art.10459' target='_blank'>https://doi: 10.1002/art.10459
  46. Metzler C, Fink C, Lamprecht P, Gross W, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology (Oxford). 2004; 43(3): 315-320. https://doi.org/ 10.1093/rheumatology/keh009
  47. Molloy E.S, Langford C.A. Does the dose of methotrexate influence the rate of relapse in patients with Wegener’s granulomatosis? Nat Clin Pract Rheumatol. 2008; 4(1): 12-13. 10.1038/ncprheum0675' target='_blank'>https://doi: 10.1038/ncprheum0675

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies